Schiavi Michele Carlo, Sciuga Valentina, Giannini Andrea, Vena Flaminia, D'oria Ottavia, Prata Giovanni, Di Tucci Chiara, Savone Delia, Aleksa Natalia, Capone Carmela, Di Mascio Daniele, Meggiorini Maria Letizia, Monti Marco, Zullo Marzio Angelo, Muzii Ludovico, Benedetti Panici Pierluigi
a Department of Gynecological and Obstetric Sciences, and Urological Sciences , Umberto I Hospital, University of Rome "Sapienza" , Rome , Italy.
b Department of Surgery-Week Surgery, Campus Biomedico , University of Rome , Rome , Italy.
Gynecol Endocrinol. 2018 Aug;34(8):666-669. doi: 10.1080/09513590.2018.1441398. Epub 2018 Feb 20.
The aim of this study was to assess the effectiveness of ospemifene in the improvement of sexual function in postmenopausal women with vulvovaginal atrophy (VVA) affected by overactive bladder syndrome (OAB) or urge urinary incontinence (UUI). One hundred five postmenopausal patients with VVA affected by OAB and/or UUI were enrolled for the study. All patients received ospemifene 60 mg for 12 weeks. Clinical examination, 3-d voiding diary and the vaginal health index (VHI) were performed at baseline and at 12 weeks. Patients completed the OAB-Q SF, FSFI, FSDS, and SF-36 questionnaires. The patient's satisfaction was also calculated. After 12 weeks, the reduction of urinary symptoms was observed. The OAB-Q symptoms, OAB-Q (HRQL) score were (55.34 ± 13.54 vs. 23.22 ± 9.76; p < .0001) and (22.45 ± 9.78 vs. 70.56 ± 15.49; p < .0001), before and after treatment. SF-36 questionnaire showed a significant improvement (p < .0001). VHI score increased and the women who regularly practice sexual activity increased after treatment. The total FSFI score increased significantly and the FSDS score changed after 12 weeks (p < .0001). The PGI-I after 12 weeks showed a total success rate of 90.5%. Ospemifene is an effective potential therapy for postmenopausal women with VVA affected by OAB or UUI improving sexual function and quality of life.
本研究的目的是评估奥昔布宁对患有膀胱过度活动症（OAB）或急迫性尿失禁（UUI）的绝经后外阴阴道萎缩（VVA）女性性功能改善的有效性。105例患有OAB和/或UUI的绝经后VVA患者被纳入研究。所有患者接受60mg奥昔布宁治疗12周。在基线和12周时进行临床检查、3天排尿日记和阴道健康指数（VHI）评估。患者完成OAB-Q SF、FSFI、FSDS和SF-36问卷，并计算患者满意度。12周后，观察到泌尿症状有所减轻。治疗前后，OAB-Q症状、OAB-Q（HRQL）评分分别为（55.34±13.54 vs. 23.22±9.76；p<.0001）和（22.45±9.78 vs. 70.56±15.49；p<.0001）。SF-36问卷显示有显著改善（p<.0001）。治疗后VHI评分增加，经常进行性活动的女性增多。12周后，FSFI总分显著增加，FSDS评分发生变化（p<.0001）。12周后的PGI-I显示总成功率为90.5%。奥昔布宁是一种有效的潜在治疗方法，可改善患有OAB或UUI的绝经后VVA女性的性功能和生活质量。
